Get insights from Vertex Pharmaceuticals' Q3 2025 earnings call—revenue growth, pipeline milestones, and outlook for ALYFTREK, CASGEVY, and JOURNAVX.
But what happens if a person wants to donate a kidney not to a family member, but to a friend or even a stranger? The law ...
We recently published 10 Stocks With Easy 20-40% Gains. Travere Therapeutics, Inc. (NASDAQ:TVTX) is one of the last week’s ...
Oral presentation to share first-of-its-kind longitudinal gene expression data in IgA nephropathy, unveiling novel insights into the mechanism of ...
To the untrained eye, Viking Creek is easy to overlook. Hemmed in by the busy boulevard connecting downtown Whitefish to its ...
Cybin Inc. (Cboe CA:CYBN) ("Cybin" or the "Company"), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental healthcare through proprietary drug discovery ...
The biotechnology market is entering a new growth phase, driven by the convergence of genomic science, artificial intelligence, and precision medicine.
Verywell Health on MSN
More Price Cuts Are Coming for Diabetes Drugs. Here's What to Expect in 2026
Insulin costs have declined over the past two years, and additional price cuts are expected in 2026. Medicare will lower prices for several diabetes drugs, including Januvia and Jardiance. Federal and ...
When temperatures plummet and snow piles up, it's always a good idea to stock the emergency kit in your car with food that's ...
About NEXICART-2 NEXICART-2 (NCT06097832) is an ongoing multi-site U.S. Phase 1/2 clinical trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory AL Amyloidosis, with a registrational ...
Lumeris, a leader in healthcare technology and services, today announced the formation of a coalition - Collaborative for Healthy Rural America (CHRA)tm. Formed to help state leaders accelerate their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback